CD39 Recombinant Rabbit monoclonal Antibody IgG
Fig1: Western blot analysis of CD39 on different cell lysate using anti-CD39 antibody at 1/1,000 dilution.
Lane 1: Human spleen
Lane 2: Mouse placenta
Lane 3: Mouse spleen
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-CD39 antibody. Counter stained with hematoxylin.
Fig3: Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-CD39 antibody. Counter stained with hematoxylin.
Host Species; Species ReactivityRabbit; Human, Mouse, Rat
Application SummaryWB, IHC
Purification; FormulationProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
ALTnamesEctonucleoside triphosphate diphosphohydrolase 1, Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, Lymphoid cell activation antigen
BackgroundCD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP and ultimately generating adenosine. Intracellular CD39 undergoes glycosylation at 6 N-glycosylation sites and translocates to the membrane in order to be an active enzyme. Alternative splicing gives rise to three CD39 isoforms, vascular, placenta I and placenta II. The placenta I isoform differs at the amino terminus whereas the placenta II isoform is missing amino acids 300-510 at the C-terminus. CD39 is expressed in vascular tissues including placenta, lung, skeletal muscle and kidney, as well as endothelium, smooth muscle, cardiac cells, lymphocytes (such as activated B cells) activated NK cells, macrophages, dendridic cells and platelets. CD39 may be used as an anti-thrombic agent for pre-treating patients at risk for coronary artery occlusion and thrombic stroke.(ET1704-74)